San Diego-based Janux calls its platform Tumor Activated T Cell Engager, or TRACTr. This technology designs a T cell engager with a “mask” that inhibits activation of the immune cell in ...

To register for the event, please click here. Janux’s TRACTr and TRACIr Pipeline Janux’s first clinical candidate, JANX007, is a TRACTr that targets PSMA and is being investigated in a Phase 1 ...

This is an exciting day for Janux, but more importantly the prostate cancer patients we serve.” Updated interim, clinical data for PSMA-TRACTr JANX007 in mCRPC as of November 15, 2024 JANX007 ...

"With these results, we believe that Janux has further demonstrated the therapeutic window-widening value proposition of their 'masked' tumor-conditional T-cell engager (TCE) platform, TRACTr ...

(Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr ...

Janux’s first clinical candidate, JANX007, is a TRACTr that targets prostate-specific membrane antigen (PSMA) and is being investigated in a Phase 1 clinical trial in adult patients with mCRPC.

Janux’s TRACTr and TRACIr Pipeline Janux’s first clinical candidate, JANX007, is a TRACTr that targets prostate-specific membrane antigen (PSMA) and is being investigated in a Phase 1 clinical ...

Janux Therapeutics is an interesting stock as this US developer of Tumor Activated T Cell Engager [TRACTr] and Tumor Activated Immunomodulator [TRACIr] immunotherapies has some catalysts for ...

"2024 was an exceptional year for Janux as we displayed the potential power of our TRACTr platform in the clinic. We believe the data recently presented from JANX007 demonstrated substantial ...

Janux’s first clinical candidate, JANX007, is a TRACTr that targets PSMA and is being investigated in a Phase 1 clinical trial in adult subjects with mCRPC. Janux’s second clinical candidate ...